Rupak Thapa, MD
Rheumatology · Winston Salem, NCNPI 1689807216
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,302 of the $1,837 with a category attached, or 70.9%. Biogen accounts for 93.6% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for rheumatology clinicians in NC, where the typical reported total is $3,350.
Across 16 payments — averaging $114.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2K
- AstraZeneca$117
Across 39 payments — averaging $5772.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$162K
- AbbVie$40K
- UCB SA$23K
What the payments were for
- Travel & lodging$1,30271%
- Food & beverage$53529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 14 | $1,719 |
| AstraZeneca | 2 | $117 |
How this compares
$1,837 in reported general payments places this provider in the 45th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 116 | $1,142,115 |
| Enbrel SureclickEtanercept | 71 | $607,870 |
| SimponiGolimumab | 30 | $203,258 |
| Xeljanz XrTofacitinib Citrate | 31 | $201,742 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $183,082 |
| Humira(Cf)Adalimumab | 12 | $156,174 |
| Actemra ActpenTocilizumab | 44 | $121,650 |
| RinvoqUpadacitinib | 17 | $103,447 |
| OrenciaAbatacept | 18 | $96,364 |
| EnbrelEtanercept | 13 | $95,170 |
| Taltz SyringeIxekizumab | 12 | $78,009 |
| KevzaraSarilumab | 15 | $61,712 |
| OtezlaApremilast | 12 | $29,492 |
| Hydroxychloroquine Sulfate | 240 | $9,256 |
| Mycophenolate Mofetil | 36 | $5,944 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Winston Salem
- Julio BravoWinston Salem$52K
- Nilamadhab MishraWinston Salem$31K
- Elliott SembleWinston Salem$9K
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.